Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sigyn Therapy
  • Therapeutic Opportunities
    • Overview
    • Sepsis
    • Community Acquired Pneumonia
    • Emerging Pandemic Threats
    • ESRD Inflammation and Endotoxemia
  • News
    • Press Releases
    • Presentations
    • Resources
  • Media
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Email Alerts
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • CEO Notes

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Email Alerts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 31, 2023 9:45am EDT

Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K

Nov 15, 2022 7:30am EST

Sigyn Therapeutics Announces Third Quarter 2022 Financial Results

Oct 13, 2022 8:30am EDT

Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy

Oct 06, 2022 8:30am EDT

Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Oct 04, 2022 9:00am EDT

Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel

Sep 14, 2022 9:00am EDT

Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients

Aug 15, 2022 9:40am EDT

Sigyn Therapeutics Announces Second Quarter 2022 Financial Results

Aug 03, 2022 6:30am EDT

Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange

Apr 26, 2022 8:00am EDT

Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board

Mar 31, 2022 8:30am EDT

Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

  • 1
  • 2
  • 3
  • 4
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 Sigyn Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap